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Left subclavian artery coverage during thoracic
endovascular aortic aneurysm repair does not
mandate revascularization
Thomas S. Maldonado, MD,a David Dexter, MD,a Caron B. Rockman, MD,a Frank J. Veith, MD,a
Karan Garg, MD,a Frank Arko, MD,b Hernan Bertoni, MD,c Sharif Ellozy, MD,d William Jordan, MD,e
and Edward Woo, MD,f New York, NY; Dallas, Tex; Buenos Aires, Argentina; Birmingham, Ala; and
Philadelphia, Pa
Objective: This study assessed the risk of left subclavian artery (LSA) coverage and the role of revascularization in a large
population of patients undergoing thoracic endovascular aortic aneurysm repair.
Methods: A retrospective multicenter review of 1189 patient records from 2000 to 2010 was performed. Major adverse
events evaluated included cerebrovascular accident (CVA) and spinal cord ischemia (SCI). Subgroup analysis was
performed for noncovered LSA (group A), covered LSA (group B), and covered/revascularized LSA (group C).
Results: Of 1189 patients, 394 had LSA coverage (33.1%), and 180 of these patients (46%) underwent LSA revascular-
ization. In all patients, emergency operations (9.5% vs 4.3%; P  .001), renal failure (12.7% vs 5.3%; P  .001),
hypertension (7% vs 2.3%; P  .01), and number of stents placed (1  3.7%, 2  7.4%, >3  10%; P  .005) were
predictors of SCI. History of cerebrovascular disease (9.6% vs 3.5%; P  .002), chronic obstructive pulmonary disease
(9.5% vs 5.4%; P .01), coronary artery disease (8.5% vs 5.3%; P .03), smoking (8.9% vs 4.2%) and female gender (5.3%
men vs 8.2% women; P  .05) were predictors of CVA. Subgroup analysis showed no significant difference between
groups B and C (SCI, 6.3% vs 6.1%; CVA, 6.7% vs 6.1%). LSA revascularization was not protective for SCI (7.5% vs 4.1%;
P .3) or CVA (6.1% vs 6.4%; P .9). Womenwho underwent revascularization had an increased incidence of CVA event
compared with all other subgroups (group A: 5.6% men, 8.4% women, P  .16; group B: 6.6% men, 5.3% women, P 
.9; group C: 2.8% men, 11.9% women, P  .03).
Conclusions: LSA coverage does not appear to result in an increased incidence of SCI or CVA event when a strategy of
selective revascularization is adopted. Selective LSA revascularization results in similar outcomes among the three cohorts
studied. Revascularization in women carries an increased risk of a CVA event and should be reserved for select cases.
(J Vasc Surg 2013;57:116-24.)
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rLeft subclavian artery (LSA) coverage is necessary to
achieve proximal seal in up to 40% of patients treated with
thoracic endovascular aortic aneurysm repair (TEVAR).1
The management of the LSA in this cohort of patients
remains controversial. Studies in support of routine pre-
operative LSA revascularization show that coverage of
the LSA during TEVAR is associated with an increased
risk of stroke, paraplegia, and arm ischemia.2-4 Other
studies show that intentional coverage of the LSA with-
out revascularization is not associated with increased
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116orbidity and lend support to those who advocate more
elective LSA revascularization during TEVAR (ie, in
hose patients with patent left internal mammary artery
LIMA)–coronary bypass, dominant or isolated left ver-
ebral artery, or a functioning left upper extremity dialysis
rteriovenous fistula).5-7
Discordant outcomes in these various studies are likely
he result of small sample size, diverse aortic pathologies
reated, inconsistent patient comorbidities, and anatomic
actors being compared or a diverse etiology of strokes and
araplegia. Indeed, a 2009 consensus statement by the
ociety for Vascular Surgery (SVS) acknowledged the qual-
ty of existing evidence describing outcomes after LSA
overage during TEVAR to be “very low” (Level C evi-
ence). Nonetheless, the proposed SVS guidelines “sug-
est” routine preoperative revascularization of the LSA for
lective cases requiring coverage of the origin of this great
essel.8
The goal of our study was to provide a more robust
eal-world experience (albeit representative of specialty ter-
iary care centers) to shed further light on the controversial
ssue of routine or mandatory LSA revascularization. We
xamined the outcomes from six high-volume centers that
erform selective LSA revascularization before TEVAR and
eport observed neurologic outcomes. This was a retro-
pective, nonrandomized study design.
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The records of 1189 consecutive patients who under-
went TEVAR at six high-volume centers from 2000 to
2010 were retrospectively reviewed. Institutional Review
Board approval was obtained. Each center performed a
minimum of 150 TEVAR. Grafts used included the TAG
(W. L. Gore and Associates, Flagstaff, Ariz) in 700 patients
(58.8%), the Talent (Medtronic, Minneapolis, Minn) in
308 (25.9%), the TX2 (Cook, Bloomington, Ind) in 89
(7.5%), and the Bolton Relay (Bolton Medical, Spain) in 44
(3.7%). The remaining 68 patients (5.7%) had thoracic
stent grafts placed that were not identified on retrospective
record review.
Patient demographics, indication for operation (aneu-
rysm, dissection, ulcer, trauma, coarctation), comorbidi-
ties, urgency of operation (elective vs emergency [ie, rup-
tured and/or acutely symptomatic]), and surgical detail
were recorded. Graft type, number of segments inserted,
and use of intraoperative spinal drainage were also included
in the analysis. Outcome measures evaluated included cere-
brovascular accident (CVA), spinal cord ischemia (SCI),
and 30-day mortality.
CVA was defined as any clinically relevant stroke or
transient ischemic event, regardless of extent of recovery.
The distribution of ischemic events (posterior vs anterior
circulation) was not consistently documented and thus
could not be analyzed. SCI was defined as any transient or
permanent paralysis or paresis at any time after TEVAR.
Selective (rather than routine) LSA revascularization
was practiced at all centers, before or at the time of TEVAR.
The decision for LSA revascularization and technique for
LSA revascularization was physician-dependent, but none
of the centers routinely revascularized the LSA before
TEVAR. Relative indications for revascularization included
long aortic coverage and prior abdominal aortic surgery.
Absolute indications included dominant left vertebral ar-
tery, LIMA–coronary bypass, isolated left cerebral hemi-
sphere (ie, a vertebral artery that does not communicate
with the contralateral hemisphere via the basilar), and func-
tioning left upper extremity arteriovenous dialysis fistula. In
most cases, cerebrovascular imaging consisting of duplex,
computed tomography angiography, or magnetic reso-
nance angiography was obtained before elective TEVAR.
Choice of imaging, as well as definitions of relative and
absolute indications for LSA revascularization, are based on
center-specific guidelines submitted by the principal inves-
tigator from each center. Ultimately, however, the specific
choice of cerebral imaging, the decision for LSA revascu-
larization, and the use of preoperative spinal drainage were
all physician-dependent. Use of postoperative “rescue”
drainage was not considered for analysis.
Subgroup analysis was performed for noncovered LSA
(group A), covered LSA without revascularization (group
B), and covered LSA with revascularization (group C).
Further subgroup analysis was performed for only those
patients undergoing TEVAR for thoracic aortic aneurysms
(TAA). Follow-up in the study was limited to 30 days. dStandard statistical analysis was performed using SPSS
oftware (SPSS Inc, Chicago, Ill). Fisher exact test or 2
nalysis was used where appropriate to compare categoric
ariables. Significant univariate variables were used to carry
ut multivariate analysis using linear regression analysis. A
esult was considered to be statistically significant with a
alue of P  .05.
ESULTS
Demographics and comorbidities of the 1189 patients
59.1% men) studied are reported in Table I, A. Average
ge was 67.8 years (range, 17-93 years). We subsequently
valuated demographics and comorbidities by LSA cover-
ge (Table I, A), and further stratified our LSA coverage
roup into revascularization and no revascularization (Ta-
le I, B). Patients in the uncovered group (group A) tended
o have more comorbidities than those who were covered
groups B and C). They were significantly more likely to
ave coronary artery disease (CAD), peripheral arterial
able I. A, Demographics and comorbidities for the
189 patients studied
Variable No (%)
Male gender 702/1189 (59.1)
Smoking 619/1149 (53.8)
CAD 496/1160 (42.7)
Diabetes 201/1159 (17.3)
Dyslipidemia 555/1162 (47.8)
Renal failure 158/1160 (13.6)
Hypertension 986/1162 (84.9)
COPD 359/1160 (30.9)
PAD 253/877 (28.8)
Cerebrovascular disease 166/877 (18.9)
Prior aortic surgery 187/791 (23.6)
AD, Coronary artery disease; COPD, chronic obstructive pulmonary dis-
ase; PAD, peripheral arterial disease.
able I. B, Demographics and comorbidities with and
ithout left subclavian artery (LSA) coverage
ariable
Uncovered LSA
(Group A)
No. (%)
Covered LSA
(Group B  C)
No. (%) P
ale gender 451/790 (57.1) 248/394 (62.9) .06
moking 422/760 (55.5) 196/387 (50.6) .118
AD 360/765 (47.1) 136/393 (34.6) .001
iabetes 133/765 (17.4) 68/392 (17.3) .987
yslipidemia 389/767 (50.7) 166/393 (42.2) .006
enal failure 119/765 (15.6) 39/393 (9.9) .009
ypertension 646/767 (84.2) 339/393 (86.3) .387
OPD 255/765 (33.3) 104/393 (26.5) .019
AD 186/570 (32.6) 67/306 (21.9) .001
erebrovascular
disease 112/570 (19.6) 54/306 (17.6) .527
rior aortic
surgery 112/514 (21.8) 75/277 (27.1) .097
AD, Coronary artery disease; COPD, chronic obstructive pulmonary dis-
ase; PAD, peripheral arterial disease.isease, renal failure, chronic obstructive pulmonary disease
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January 2013118 Maldonado et al(COPD), and dyslipidemia (Table I, B). Group C patients
had significantly more CAD, dyslipidemia, renal failure,
and COPD than patients in group B (Table I, C). Comor-
bidity profile was more evenly matched in the TAA cohort
(see below).
TEVAR was most commonly performed to treat aneu-
rysmal disease of the thoracic aorta (69.2%; Table II). All
centers practiced selective revascularization (range, 27.6%
to 58.8%; P .005). Octogenarians were more likely to die
by 30 days (19.8% vs 10.5%; P  .0001) but were not at
significantly increased risk of stroke or SCI than nonocto-
genarians.
Major adverse events. The incidence of major adverse
events (MAEs), including any SCI, any stroke, and death at
30 days is reported in Table III, A. There was no significant
difference in SCI or stroke among centers. There was also
no difference in MAE risk by device type.
SCI related to urgency of operation (9.5% emergency
vs 4.3% elective; P  .001), renal failure (12.7% vs 5.3%;
P  .001), hypertension (7% vs 2.3%; P  .01), intraoper-
ative use of spinal drainage (10.0% vs 4.5%; P  .003) and
number of endografts placed (1  3.7%, 2  7.4%, 2 
10%; P  .005) were significantly associated with SCI
Table I. C, Demographics and comorbidities with and
without left subclavian artery (LSA) revascularization
Variable
Covered LSA
P
No
revascularization
(Group B)
No. (%)
With
revascularization
(Group C)
No. (%)
Male gender 136/212 (64.2) 106/173 (61.3) .597
Smoking 101/207 (48.8) 95/171 (55.6) .215
CAD 58/211 (27.5) 73/173 (42.2) .003
Diabetes 34/211 (16.1) 32/172 (18.6) .587
Dyslipidemia 76/211 (36.0) 86/173 (49.7) .007
Renal failure 28/211 (13.3) 10/173 (5.8) .016
Hypertension 188/211 (89.1) 144/173 (83.2) .101
COPD 42/211 (19.9) 61/173 (35.3) .001
PAD 29/148 (19.6) 35/149 (23.5) .481
Cerebrovascular
disease 20/148 (13.5) 30/149 (20.1) .163
Prior aortic
surgery 35/133 (26.3) 37/135 (27.4) .891
CAD, Coronary artery disease; COPD, chronic obstructive pulmonary dis-
ease; PAD, peripheral arterial disease.
Table II. Indications for thoracic endovascular aortic
aneurysm repair (TEVAR)
Indication No. (%)
Aneurysm 823 (69.2)
Dissection 155 (13.0)
Ulcer 61 (5.1)
Trauma 75 (6.3)
Coarctation 75 (6.3)(Table IV, A). On multivariate analysis, only urgency of operation (P  .002), renal failure (P  .011), and intra-
perative use of spinal drainage (P  .01) remained signif-
cant (Table IV, B).
Stroke (CVA) related to history of cerebrovascular
isease (9.6% vs 3.5%; P  .002), COPD (9.5% vs 5.4%;
 .01), CAD (8.5% vs 5.3%; P  .03), smoking (8.9% vs
.2%; P  .02), and female gender (5.3% men vs 8.2%
omen; P  .5) were significantly associated with CVA
Table V, A). On multivariate analysis, only a history of
erebrovascular disease (P .01), smoking (P .023), and
emale gender (P .046) remained significantly associated
ith CVA (Table V, B).
Mortality at 30 days related to urgency of operation
15.6% emergency vs 9.7% elective; P  .003), indication
or surgery (penetrating ulcer disease, 21.3% vs 11.4%; P
02), renal failure (22.7% vs 10.4%; P .0001), and COPD
15.6% vs 10.5%; P  .013) were predictive of 30-day
ortality, whereas dyslipidemia was protective for 30-day
ortality (9.6% vs 14.4%; P  .012; Table VI, A). Multi-
ariate analysis maintained renal failure (P  .001) and
OPD (P  .002) as predictors of 30-day mortality, and
yslipidemia (P  .003) and elective status (P  .011)
emained protective for death (Table VI, B).
LSA coverage. Of 1189 patients, 394 had LSA cover-
ge (33.1%) (groups B and C) and 795 (66.9%) patients did
ot (group A). LSA coverage was not significantly associ-
ted with SCI (6.1% covered vs 6.3% not covered; P .87),
VA (6.1% covered vs 6.7% not covered; P  .69), or
0-day mortality (9.9% covered vs 13.7% not covered; P 
063; Table VII). Of the 394 patients who had LSA cover-
ge, 180 (46%) underwent LSA revascularization (group
), whereas the remaining 214 patients (54%) had the LSA
overed without revascularization (group B). Subgroup
nalysis showed no significant difference in outcome mea-
ures between groups B and C for SCI (7.5% vs 4.1%; P 
2), CVA (6.1% vs 6.4%; P  .9), or death (11.3% vs 7.5%;
 .5; Table VIII). Although female gender was predictive
f CVA in all TEVAR patients, in subset analysis this was
nly true in women who underwent LSA revascularization
group A: 5.6% men, 8.4% women, P .16; group B: 6.6%
en, 5.3% women, P  .9; group C: 2.8% men, 11.9%
omen, P  .03; Table IX, B). CVA rates were not signif-
cantly different between groups with regard to urgency
nd indications (Table IX, B). SCI rates were not signifi-
antly different between groups with regard to indications
able III. A, Major adverse events (MAEs), including
araplegia, stroke, and death, after thoracic endovascular
ortic aneurysm repair (TEVAR) (n  1189) for all
athologies (n  1189)
Event No. (%)
Paraplegia 74/1189 (6.2)
Stroke 77/1189 (6.5)
Mortality at 30 days 147/1189 (12.4)
Total MAEs 218/1189 (18.3)r gender. However, SCI rates were higher in group B
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vs 2.3%, P .015; group C: 4.7% vs 3.9%, P .83) as well
as in those group B patients who had spinal drainage (Table
IX, A).
TAA cohort. Demographics and comorbidities were
evaluated among groups. Groups B and C were well
matched with the exception of hypertension (93% group B
vs 82% group C; P  .008) and COPD (26% group B vs
39% group C; P  .029). A total of 823 patients undergo-
ing TEVAR for TAA were studied (628 elective, 183
emergency). MAEs are reported in Table III, B. Emergency
Table III. B, Major adverse events (MAEs), including par
aneurysm repair (TEVAR) for thoracic aortic aneurysms (T
Event
T
All repairs
Paraplegia 46/809 (5.6)
Stroke 59/810 (7.2)
Mortality at 30 days 97/822 (11.8)
Total MAEs 147/822 (17.9)
aComparing elective vs emergency TAA.
Table III. C, Major adverse events (MAEs), including
paraplegia, stroke, and death after thoracic endovascular
aortic aneurysm repair (TEVAR) for all thoracic aortic
aneurysms (TAA) (n  823) comparing group B (left
subclavian artery [LSA] covered without
revascularization) and C (LSA covered and
revascularized)
Event
All TAA repairs, No. (%)
PGroup B Group C
Paraplegia 5/111 (4.5) 6/136 (4.2) .914
Stroke 5/106 (4.5) 11/132 (7.7) .3
Mortality at 30 days 14/111 (12.6) 9/143 (6.3) .08
Total MAEs 21/111 (18.9) 22/143 (15.3) .456
Table III. D, Major adverse events (MAEs), including
paraplegia, stroke, and death following thoracic
endovascular aortic aneurysm repair (TEVAR) for elective
thoracic aortic aneurysms (TAA) (n  628) comparing
groups B (left subclavian artery [LSA] covered without
revascularization) and C (LSA covered and
revascularized)
Event
Elective repair, No. (%)
PGroup B Group C
Paraplegia 2/74 (2.7) 5/119 (4.2) .588
Stroke 4/74 (5.4) 7/119 (5.9) .889
Mortality at 30 days 6/74 (8.1) 9/119 (7.6) .549
Total MAEs 11/74 (14.9) 16/119 (13.4) .782status resulted in significantly worse outcomes for SCI p9.3% vs 4.6%; P  .016), mortality (22.9% vs 8.7%), and
otal MAEs (30.1% vs 14.5%; P  .001).
Of 823 patients undergoing TEVAR for TAA, 254 had
SA coverage (31.3%; groups B and C) and 557 (68.7%)
ia, stroke, and death after thoracic endovascular aortic
epair, No. (%)
PaElective Emergency
627 (4.6) 17/182 (9.3) .016
627 (6.7) 17/183 (9.3) .235
627 (8.7) 42/183 (22.9) .001
628 (14.5) 55/183 (30.1) .001
able IV. A, Spinal cord ischemia (SCI) after thoracic
ndovascular aortic aneurysm repair (TEVAR) (n 
189)
ariable No. % P
rgency
Elective 0/670 4.30 .001
Emergent 44/463 9.50
ndication
Aneurysm 5.60 .108
Ulcer 5.10 .638
Dissection 9.00 .076
Trauma 8.00 .544
Coarctation 8.00 .544
moking .59
Yes 41/618 6.60
No 31/529 5.90
AD 37/495 8.00 .157
iabetes 17/201 8.50 .167
yslipidemia 38/554 6.90 .448
enal failure
Yes 20/157 12.70 .001
No 53/1001 5.30
ypertension
Yes 69/984 7.00 .017
No 4/176 2.30
OPD 24/359 6.70 .72
AD
Yes 20/252 7.90 .072
No 30/623 4.80
erebrovascular disease 13/166 7.80 .192
ender
Male 40/702 5.70 .368
Female 34/487 7.00
rior aortic surgery 10/187 5.30 .69
pinal drainage
Yes 23/231 10.00 .003
No 28/616 4.50
tent graft components
implanted, No.
1 15/405 3.70 .005
2 29/392 7.40
3 25/251 10.00
AD, Coronary artery disease; COPD, chronic obstructive pulmonary dis-
ase; PAD, peripheral arterial disease.apleg
AA)
AA r
29/
42/
55/
91/atients did not (group A). Of the 254 patients who had
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(group C) and the remaining 111 patients (44%) had the
LSA covered without revascularization (group B). Sub-
group analysis showed no significant difference in outcome
measures for neurologic adverse events between groups B
and C (SCI, 4.5% vs 4.2%, P .9; CVA, 4.5% vs 7.7%, P
Table IV. B, Multivariate analysis for spinal cord
ischemia (SCI)a
Variable OR (95% CI) P
Elective status 0.38 (0.204-0.710) .002
Hypertension 2.63 (0.788-8.775) .166
Lumbar drain 2.33 (1.226-4.410) .01
Renal failure 2.54 (1.236-5.228) .011
No. of stents implanted 1.35 (0.907-2.013) .139
CI, Confidence interval; OR, odds ratio.
aOn multivariate analysis, only urgency of operation (P .002), renal failure
(P  .011), and intraoperative use of lumbar drain (P  .01) remained
significant predictors (Table IV, A).
Table V. A, Stroke and after thoracic endovascular aortic
aneurysm repair (TEVAR) (n  1189)
Variable No. % P
Urgency
Elective 2/694 6.10 .318
Emergent 5/464 7.50
Indication
Aneurysm 0.20 .155
Ulcer 0.60 .133
Dissection 6.70 .920
Trauma 2.70 .163
Coarctation 2.70 .163
Smoking
Yes 55/619 8.90 .001
No 22/529 4.20
CAD
Yes 42/496 8.50 .031
No 35/663 5.30
Diabetes 18/201 9.00 .149
Dyslipidemia 41/555 7.40 .267
Renal failure 9/157 5.70 .622
Hypertension 68/985 6.90 .379
COPD
Yes 34/359 9.50 .010
No 43/800 5.40
PAD 14/253 5.50 .446
Cerebrovascular disease
Yes 16/166 9.60 .001
No 25/710 3.50
Gender
Male 37/702 5.30 .042
Female 40/487 8.20
Prior aortic surgery: yes vs no 12/187 6.90 .197
Spinal drainage: yes vs no 15/231 6.50 .168
No. of stents implanted
1 20/405 4.90 .07
2 26/392 6.60
3 24/251 9.60
CAD, Coronary artery disease; COPD, chronic obstructive pulmonary dis-
ease; PAD, peripheral arterial disease..3). There was a trend toward increased mortality noted in ehose patients whose LSA was covered but not revascular-
zed (12.6% group B vs 6.3% group C; P  .08), which
pproached statistical significance (Table III, C). However,
hen only elective TAA were evaluated, there was no
ifference noted in mortality (Table III, D).
ISCUSSION
TEVAR requires an adequate “seal zone” of the cov-
able V. B, Multivariate analysis for strokea
ariable OR (95% CI) P
emale gender 1.941 (1.013-3.720) .046
AD 0.985 (0.514-1.888) .964
OPD 1.614 (0.0828-3.145) .160
erebrovascular disease 2.423 (1.237-4.592) .01
moking 2.267 (1.119-4.592) .023
AD, Coronary artery disease; CI, confidence interval; COPD, chronic
bstructive pulmonary disease; CVA, cerebrovascular accident; OR, odds
atio.
Only a history of cerebrovascular disease (P  .01), smoking (P  .023),
nd female gender (P  .046) remained significant predictors of CVA.
able VI. A, Thirty-day mortality after thoracic
ndovascular aortic aneurysm repair (TEVAR)
ariable No. % P
rgency
Elective 67/693 9.70 .003
Emergency 72/493 15.60
ndication
Aneurysm 11.80 .831
Ulcer 21.3 .02
Dissection 9.60 .245
Trauma 14.70 .45
Coarctation 13.50 .664
moking 68/617 11.00 .215
AD 63/495 12.70 .572
iabetes 21/201 10.40 .427
yslipidemia
Yes 53/554 9.60 .012
No 87/605 14.40
enal failure
Yes 36/158 22.80 .0001
No 104/999 10.40
ypertension 115/983 11.70 .348
OPD
Yes 56/358 15.60 .013
No 84/799 10.50
AD 35/251 13.90 .710
erebrovascular disease 19/166 11.40 .441
ender
Male 89/702 12.70 .639
Female 57/487 22.80
rior aortic surgery: yes vs no 20/187 10.70 .127
pinal drainage 24/231 10.40 .067
o. of stents implanted
1 30/403 7.40 .001
2 47/392 12.0
3 44/250 17.60
AD, Coronary artery disease; COPD, chronic obstructive pulmonary dis-
ase; PAD, peripheral arterial disease.red stent graft both proximal and distal to the area of
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Volume 57, Number 1 Maldonado et al 121disease to be treated. In nearly one-third of patients, this
proximal seal zone involves covering the LSA.1 The man-
agement of the LSA in the setting of intentional coverage
during TEVAR remains controversial. Some surgeons re-
vascularize selectively, whereas others do so routinely. Our
research was intended to examine the use of selective rather
than mandatory revascularization of the LSA by reviewing
the outcomes of 1000 patients from six high-volume
centers. This multicenter study provides the most robust
experience to date on TEVAR and management of cover-
age of the LSA origin. Furthermore, it represents real-
world (albeit at tertiary care centers) experience rather than
data from clinical trials.
Given the extensive circulation provided by the LSA,
coverage with stent grafting may not be inconsequential.
Stroke, SCI, coronary ischemia (in the setting of a LIMA
Table VI. B, Risk of 30-day mortality in all patients
undergoing thoracic endovascular aortic aneurysm repair
(TEVAR) by multivariate analysis
Variable OR (95% CI) P
Elective status 0.574 (0.396-0.832) .003
Ulcer 1.828 (0.942-3.547) .075
Renal failure 2.348 (1.513-3.613) .001
COPD 1.840 (1.248-2.712) .002
Dyslipidemia 0.607 (0.414-0.890) .011
CI, Confidence interval; COPD, chronic obstructive pulmonary disease;
OR, odds ratio.
Table VII. Risk of spinal cord ischemia (SCI),
cerebrovascular accident (CVA), and death at 30 days in
patients undergoing thoracic endovascular aortic
aneurysm repair (TEVAR) with left subclavian artery
(LSA) noncovered (group A) vs covered (group B  C)
Group
SCI CVA Death
No. (%) No. (%) No. (%)
Group A 50/791 (6.3) 53/791 (6.7) 108/789 (13.7)
Group B  C 24/393 (6.1) 24/394 (6.1) 39/394 (9.9)
P .87 .69 .063
Table VIII. Risk of spinal cord ischemia (SCI),
cerebrovascular accident (CVA), and death at 30 days in
patients undergoing thoracic endovascular aortic
aneurysm repair (TEVAR) with coverage of left
subclavian artery (LSA) with (group C) and without
revascularization (group B)
Group
SCI CVA Death
No. (%) No. (%) No. (%)
Group B 16/212 (7.5) 13/212 (6.1) 24/212 (11.3)
Group C 7/172 (4.1) 11/173 (6.4) 13/173 (7.5)
P .2 .9 .5bypass), as well as arm ischemia have all been described.9 sontradictory opinions have emerged for management of
he LSA during TEVAR. Some support routine or manda-
ory preoperative revascularization via either a left common
arotid artery-to-LSA bypass or an LSA transposition, citing
higher rate of stroke or SCI in patients with LSA coverage
ithout revascularization.3,4,10 Alternatively, proponents
f selective LSA revascularization agree that patients with
bsolute indications (ie, LIMA bypass, left vertebral dom-
nance, isolated left brain hemisphere, left upper extremity
ialysis access, etc) warrant prior LSA revascularization but
rgue that other patients can be revascularized more selec-
ively based on risk stratification. Specifically, patients with
ompromised spinal cord collateral flow (ie, prior aortic
able IX. A, Risk of spinal cord ischemia (SCI) at 30
ays in patients undergoing thoracic endovascular aortic
neurysm repair (TEVAR) with coverage of left
ubclavian artery (LSA) with (group C) and without
group B) revascularization according to urgency,
ndication, use of spinal drain, and gender
ariable
Group B
P
Group C
PNo. (%) No. (%)
rgency
Emergency 14/123 (11.4) .015 2/43 (4.7) .831
Elective 8/86 (2.3) 5/128 (3.9)
ndication
Aneurysm 5/109 (4.6) .22 6/143 (4.2) .92
Dissection 7/67 (10.4) 1/19 (5.3)
Ulcer 2/10 (20) 0/5 (0)
Trauma 2/23 (8.7) 0/5 (0)
pinal drain 4/42 (9.5)
Yes 6/139 (15) .021 2/99 (2) .44
No 4/99 (4)
ender
Female 6/76 (7.9) .89 4/67 (6.0) .31
Male 10/136 (7.4) 3/105 (2.9)
able IX. B, Risk of stroke (CVA) at 30 days in patients
ndergoing thoracic endovascular aortic aneurysm repair
TEVAR) with coverage of left subclavian artery (LSA)
ith (group C) and without (group B) revascularization
ccording to urgency, indication, and gendera
ariable Group B P Group C P
rgency
Emergency 9/123 (7.3) .432 4/44 (9.1) .4
Elective 4/86 (4.7) 7/128 (5.5)
ndication
Aneurysm 5/109 (4.6) .52 11/144 (7.6) .5
Dissection 6/67 (9.0) 0/19 (0)
Ulcer 0/10 (0) 0/5 (0)
Trauma 1/23 (4.3) 0/5 (0)
ender
Female 4/76 (5.3) .9 8/67 (11.9) .03
Male 9/136 (6.6) 3/106 (2.8)
Only female gender differed between groups, with an increased risk of
troke in female patients undergoing left subclavian artery revascularizationurgery, occluded internal iliac artery, plan for long-segment
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January 2013122 Maldonado et althoracic aortic coverage, or pre-existing small vessel occlu-
sive disease such as seen in renal failure) should be consid-
ered for LSA revascularization to preserve LSA collateral
flow to the spine.5-7,9,11 Furthermore, the relatively rare
complication of arm ischemia after LSA coverage during
TEVAR has been shown to be adequately managed with
postoperative LSA revascularization.12 Our study does not
address postoperative arm ischemia because this variable
was inconsistently reported among centers.
Most literature on LSA revascularization is limited to
patients with cerebrovascular disease, which may limit our
ability to extrapolate these risks for aortic pathologies.
Nonetheless, LSA revascularization is not entirely benign.
Risks include CVA and injury to the associated subclavian
artery, subclavian vein, brachial plexus, vagus nerve,
phrenic nerve, and thoracic duct.1,13,14 One large series
reported a stroke rate of 2% during carotid–subclavian
bypass,15 while phrenic nerve injury has been reported to
be as high as 12.6%.2 The incidence of other complications
are less well described in the literature.
In an effort to standardize care and improve outcomes,
the SVS put forth guidelines for management of LSA
coverage after TEVAR based on a meta-analysis of 51
studies in the literature. Most were single-institution, ret-
rospective, nonrandomized studies.2 The most compre-
hensive and largest series (n  606) was a voluntary,
self-reported, multi-institutional registry of nonconsecu-
tive patients.3 Despite self-admitted very “low quality evi-
dence,”8 the SVS Committee on Aortic Diseases concluded
that for elective TEVAR, the LSA, should be revascularized if
its origin is covered. These recommendations were based
on the premise that LSA sacrifice resulted in an increased
incidence of neurologic adverse events (SCI and stroke).
Our multicenter study represents the largest experience of
TEVAR and challenges these guidelines. Contrary to the SVS
recommendations, we conclude that selective LSA revascular-
ization appears to be safe and does not result in increased
incidence of major neurologic events (SCI and stroke).
SCI. In our series, the incidence of SCI was 6.2%. This
is comparable to other larger reviews reported in the liter-
ature.2,3,10,16 Predictors of SCI included urgency of oper-
ation, presence of renal failure, hypertension, and use of
three of more stent graft components. These factors may be
associated with compromised spinal perfusion. Urgency of
operation may result in increased rates of SCI due to
insufficient time for the spine to form collaterals, as often
occurs in more chronic aortic disease processes. In addi-
tion, emergency cases (ie, traumatic transections or aneu-
rysm ruptures, or malperfusing dissections) may present
with hypotension, posing further insult to spinal cord per-
fusion. Furthermore, emergency cases may not permit for
proper selection of patients who would otherwise have
benefited from LSA revascularization. Indeed, on sub-
group analysis, urgency of TEVAR was associated with a
significant increase in SCI for patients in group B (P 
.015) but not in group C (P .83). Hypertension as well as
renal failure may be thought of as markers for atheroscle-
rotic patients who may have minimal redundant collaterals, thus exacerbating SCI after TEVAR coverage.3 Finally, use
f three or more stent graft components suggests diffuse aortic
athology requiring extensive coverage of the thoracic aorta
nd interruption of patent segmental arteries to the spinal
ord. Unfortunately, we were not able to determine precise
ength of aortic coverage but believe that, while not ideal, the
umber of stents used is a reasonable surrogate for this. Our
ndings of renal failure and use of three or more stent grafts as
isk factors for SCI corroborate findings from the European
ollaborators on Stent-Graft Techniques for AAA and Tho-
acic Aortic Aneurysm and Dissection Repair (EUROSTAR)
egistry.3 Although the use of spinal drainage was also identi-
ed as significantly associated with SCI, this is likely reflective
f preoperative considerations that prompted spinal drainage.
ndeed, the patients who underwent spinal drainage most
ikely represent a self-selected cohort that is at increased risk
or SCI. The presence of a drain, in and of itself, is unlikely to
ontribute to SCI.
In subgroup analysis of our patients who underwent
SA origin coverage, the incidence of SCI was not signifi-
antly higher in those patients who did not have surgical
evascularization of the LSA (7.5% vs 4.1%; P  .2). This
nding directly challenges conclusions drawn from various
ther large series.3,10 Analysis of the EUROSTAR registry
ound LSA coverage without revascularization was inde-
endently correlated with SCI on multivariate analysis.3
his analysis was based on a voluntary registry of 606
atients, 159 of whom had their LSA covered. Of that
ohort, 40 had elective LSA revascularization. There were
5 instances of SCI, six occurring in the cohort consisting
f patients with a covered LSA and none among patients
ith LSA revascularization (P  .044). It is possible that
he EUROSTAR results as well as older large meta-analysis
esults showed more SCI in patients whose LSA was cov-
red because those studies were not selecting patients prop-
rly who would benefit from revascularization.
Stroke. In our study, the incidence of stroke was 6.5%,
value comparable across other reported large series.2-4,10
n multivariate analysis, history of cerebrovascular disease,
moking, and female gender were significantly associated
ith CVA. On subgroup analysis, there was no difference in
troke rates among patients undergoing LSA coverage with
r without revascularization.
The cause for strokes in patients undergoing TEVAR is
ikely multifactorial. Emboli from wire catheter manipula-
ion in atherosclerotic aortic arches can result in ischemic
vents in any distribution, whereas interruption of flow to
he vertebral artery due to direct coverage of an anomalous
rtery originating from the arch itself or, more commonly,
SA coverage generally results in posterior circulation isch-
mia. Intraoperative hypotension can result in a watershed
istribution of ischemia. Our retrospective study is limited
ecause we were unable to reliably distinguish between
nterior and posterior circulation strokes. Thus, we are
nable to speculate about the role of LSA coverage on
troke type. Moreover, any definitive conclusion regarding
tiology of stroke is difficult or impossible on any retrospec-
ive review because the cause may be multifactorial. Out-
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Volume 57, Number 1 Maldonado et al 123comes from the EUROSTAR registry found stroke was
associated with prolonged procedure duration as well as
with female gender. They noted no statistically significant
difference on subgroup analysis comparing LSA coverage
with and without revascularization.3
There has been no literature consensus on the effect of
LSA coverage with or without revascularization on periop-
erative CVA. Although a meta-analysis by Rizvi et al2
appears to support revascularization preventing CVA after
LSA coverage, several single-institution reports demon-
strate no such protection that would support mandatory
revascularization.5-7 Perhaps the most unexpected finding in
our study was that women who underwent LSA revasculariza-
tion had a fourfold higher incidence of stroke than those who
were covered but not revascularized (P .03). Female gender
was also found to be a significant predictor of stroke in the
EUROSTAR registry.3 The precise explanation for an in-
crease in stroke risk for women undergoing TEVAR is un-
clear, but we propose that women’s smaller vessels may place
them at higher risk for stroke during LSA bypass or transpo-
sition. Our finding of increased incidence of stroke in women
undergoing LSA bypass or transposition suggests that not
only is mandatory revascularization not helpful but also per-
haps is dangerous in certain cohorts of patients (ie, women).
Study limitations. As a retrospective review of pro-
spectively collected data, our study has limitations. Our
analysis was completed by combining six separate databases
with different data points collected throughout different
postoperative intervals. The absence of reliable data regard-
ing vertebral artery preoperative patency, type of LSA re-
vascularization (transposition vs bypass), as well as details of
stroke type (anterior vs posterior) limits our study. Further-
more, the variety of aortic pathologies treated represent a
real-life experience in high-volume centers but may be
confounding. Our analysis of the TAA cohort provides
more focused data for TEVAR and showed no difference in
stroke or SCI with or without LSA revascularization.
Perhaps our greatest limitation is that although the six
centers performed selective revascularization, we do not
know what criteria affected the individual physician’s deci-
sion to leave the LSA covered or to surgically revascularize.
We only know that each center practiced selective and not
mandatory revascularization. Selection bias may be partic-
ularly relevant in patients undergoing LSA revasculariza-
tion who are deemed to be at increased risk for SCI a priori.
Furthermore, although there appears to be consensus
about absolute indications for revascularization (ie, LIMA
graft), the benefit of preserving LSA flow for patients with
relative indications remains less clear. These nonstandard-
ized data limit the analysis that can be completed and
hamper our ability to make more definitive conclusions.
Although analysis of our data is limited and does not
represent conclusive “level 1” evidence, it does not carry
the problems associated with a meta-analysis and represents
the largest multicenter study to date. We believe that it
effectively calls to question whether mandatory LSA revas-
cularization is necessary. Although selective LSA revascu-
larization during TEVAR appears to be safe based on ouresults, a prospective study comparing outcomes between
igh-volume centers that perform selective revasculariza-
ion compared with similar centers that subscribe to a
ractice of mandatory revascularization may provide higher-
uality evidence to create new guidelines for management of
he LSA during TEVAR.
ONCLUSIONS
LSA coverage does not appear to result in an increased
ncidence of SCI or CVA when a strategy of selective
evascularization is adopted. Selective LSA revasculariza-
ion resulted in similar outcomes among the three cohorts
tudied. Revascularization in women carries increased risk
f CVA and should be reserved for select cases.
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